Abstract
Objective
To evaluate the efficacy and tolerability of intravenous fosphenytoin in children with status epilepticus, and resulting serum total phenytoin levels.
Methods
In this prospective study, 51 children aged less than 18 years received intravenous loading dose of fosphenytoin (18-20 mg/kg). Serum total phenytoin levels were estimated at 90 -100 minutes. Outcomes studied were (i) seizure control and local and/ or systemic adverse effects in next 24 hours and (ii) phenytoin levels and its correlation with dose received, seizure control and adverse effects.
Results
The actual dose of fosphenytoin received varied from 15.1 to 25 mg/kg. Seizures were controlled in 45 (88%) children and, two required additional dose of 10 mg/kg. None of the children showed any local or systemic adverse effects. Serum total phenytoin levels were in the therapeutic range (10-20 μg/mL) in 12 (23.5%), sub-therapeutic in 16 (31.3%) and supratherapeutic in 25 (49%) children. There was weak correlation of the phenytoin levels with dose of fosphenytoin received, seizure control, or adverse effects.
Conclusion
Intravenous fosphenytoin loading dose of 20 mg/kg is effective in controlling seizures in 88% of children with status epilepticus, with a good safety profile. Seizure control and adverse effects appear to be independent of serum total phenytoin levels achieved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mishra D, Sharma S, Sankhyan N, Konanki R, Kamate M, Kanhere S, et al. Consensus guidelines on management of childhood convulsive status epilepticus. Indian Pediatr. 2014;51:975–90.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents. 2016;16:48–61.
Poplawaska M, Borowicz K, Czuczwar SJ. The safety and efficacy of Fosphenytoin for the treatment of status epilepticus. Expert Rev Neurother. 2015; 15:983–92.
Kirschbaum K, Gurk-Turner C. PHT vs Fosphenytoin. BUMC (Baylor University Medical Center) Proceedings. 1999;12;168–72.
von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28:1391–400.
McCluggage LK, Voils SA, Bullock MR. Phenytoin toxicity due to genetic polymorphism. Neurocrit Care. 2009;10:222.
Allen FH, Jr, Runge JW, Legarda S. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus. Epilepsia. 1995;36:90.
Moffett, Brady S, Weingarten, Mindi M, Schmees, Lindsay R, et al. Fosphenytoin population pharmacokinetics in the acutely ill pediatric population. Pediatric Critical Care Med. 2018;19:748–54.
Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Edwards G, Watkins WM, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol. 2003;56:112–9.
Boucher BA, Feler CA, Michie DD, Tipton BK, Smith KR Jr, Kramer RE, et al. The safety, tolerability and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy. 1996;16:638–45.
Nishiyama M, Nagase H, Tomioka K, Tanaka T, Yamaguchi H, Ishida Y, et al. Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus. Brain Dev. 2018;40:884–90.
Fischer JH, Patel TV, Fischer PA. Fosphenytoin: Clinical pharmacokinetics and comparable advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42:33–58.
Jamerson BD, Dukes GE, Brouwer KLR, Dorm KH. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy. 1994; 14:47–52.
Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med. 2006;30:75.
Messinger MM, Moffett BS, Wilfong A. Impact of body habitus on Phenytoin levels following Fosphenytoin loading dose in pediatric patients. Ther Drug Monit. 2015;37:772–5.
Prusakoy AB, Patel AD, Ciole JW. Impact of obesity on Fosphenytoin volume of distribution in pediatric patients. J Child Neurol. 2018;33:534–36.
Kim DW, Kim TE, Ji M, Chun Yi. Safety, tolerability and pharmacokinetics of Fosphenytoin loading in patients with subarachnoid hemorrhage. Clin Neuropharmacol. 2015;38: 248–51.
Tanaka J, Kasai H, Shimizu K, Shimasaki S, Kumagai Y. Population pharmacokinetics of PHT after intravenous administration of Fosphenytoin sodium in pediatric patients, adult patients and healthy volunteers. Eur J Clin Pharmacol. 2013;69:489–97.
Selioutski O, Grzesik K, Vasilyeva ON, Hilmarsson A, Fessler J, Lin L, et al. Evaluation of phenytoin serum levels following a loading dose in the acute hospital setting. Seizure. 2017;52:199–204.
Acknowledgements
Mr. Srivallabh Sane (Statistician-Department of Community Medicine), Dr. Bhakti Sarangi (PICU Incharge), Bharati Vidyapeeth Deemed University Medical College, Pune.
Author information
Authors and Affiliations
Corresponding author
Additional information
Contributors: KS: conceptualized and planned the study, along with manuscript writing; SB, VG, RP: carried out the data collection and analysis. SR: revised the manuscript.
Funding: Institutional (Bharati Medical Foundation).
Competing interest: None stated.
Rights and permissions
About this article
Cite this article
Srivastava, K., Bhartiya, S., Gavli, V. et al. Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus. Indian Pediatr 57, 218–221 (2020). https://doi.org/10.1007/s13312-020-1754-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-020-1754-5